Newspaper publication of Un-audited Financial results (standalone & Consolidated) for Quarter and Nine- Months ended on 31st December, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Eiko Lifesciences published its Q3 FY26 and nine-month FY26 unaudited results in Financial Express and Mumbai Lakshadweep on January 30, 2026, after board approval on January 29, 2026. On a standalone basis, Q3 revenue rose to ₹1,013.01 lakhs from ₹876.21 lakhs a year ago (~15.6% YoY), while nine-month revenue grew to ₹2,769.82 lakhs from ₹2,589.76 lakhs (~7% YoY). Standalone nine-month profit after tax climbed to ₹174.08 lakhs from ₹142.55 lakhs, with Q3 standalone EPS at ₹0.69 and nine-month EPS at ₹1.79. On a consolidated basis, nine-month revenue dipped to ₹3,521.01 lakhs from ₹3,838.02 lakhs, but profit after tax jumped sharply to ₹107.50 lakhs from ₹23.86 lakhs last year, suggesting improved performance at the subsidiary Eiko Scientific Solutions LLP, Eikovivify Logistics, and associate Reflux Pharmaceuticals.
Modest standalone growth paired with a strong recovery in consolidated profits points to improving profitability in subsidiaries and associates, which is a positive signal for shareholders despite the slight dip in consolidated revenue. The numbers are small in absolute terms, so material stock price reaction is likely limited unless the consolidated profit momentum continues.